FY2026 · ended Mar 28, 2026 · Revenue $1.33B, -2.0% YoY · Filed May 20, 2026
Haemonetics Corporation (HAE) files with the SEC under industry code 3841, Surgical & Medical Instruments & Apparatus. In fiscal 2026, which ended Mar 28, 2026, it reported revenue of $1.3 billion and net income of $97.3 million. Free cash flow was $260.4 million. As of Sep 26, 2026 it held $260.7 million in cash and investments and $1.1 billion in total debt.
Revenue (TTM)
$1.38B
+4.1% vs year-ago TTM
Net income (TTM)
$103.91M
-38.2% vs year-ago TTM
Operating cash flow (TTM)
$344.93M
+19.3% vs year-ago TTM
Free cash flow (TTM)
$298.24M
+16.5% vs year-ago TTM
EPS (TTM)
$2.24
-34.7% vs year-ago TTM
Dividend per share
None
Shares outstanding
45.45M
-5.4% vs prior year
Net cash
$-875.92M
as of Sep 26, 2026
Operating margin
12.8%
FY 2027
Company profile
- Industry
- Surgical & Medical Instruments & Apparatus (SIC 3841)
- Listed as
- HAE (NYSE)
- Fiscal year ends
- April 3
- Incorporated in
- MA
- Headquarters
- Boston, MA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 313143
Other Surgical & Medical Instruments & Apparatus companies
- Stryker Corp SYK
- 3M Co MMM
- Boston Scientific Corp BSX
- Becton Dickinson & Co BDX
- Medline Inc. MDLN
- Resmed Inc RMD
- Dexcom Inc DXCM
- Fresenius SE & Co. KGaA FSNUY
All 151 Surgical & Medical Instruments & Apparatus companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2026 Mar 28, 2026 |
FY 2025 Mar 29, 2025 |
FY 2024 Mar 30, 2024 |
FY 2023 Apr 1, 2023 |
FY 2022 Apr 2, 2022 |
|---|---|---|---|---|---|
| Revenue | $1.3B | $1.4B | $1.3B | $1.2B | $993.2M |
| Operating income | $156.7M | $221.8M | $164.9M | $156.0M | $80.8M |
| Net income | $97.3M | $167.7M | $117.6M | $115.4M | $43.4M |
| Diluted EPS | $2.05 | $3.31 | $2.29 | $2.24 | $0.84 |
| Operating cash flow | $293.2M | $181.7M | $181.8M | $273.1M | $172.3M |
| Free cash flow | $260.4M | $142.4M | $143.6M | $81.7M | $75.8M |
| Total assets | $2.4B | $2.5B | $2.2B | $1.9B | $1.9B |
| Stockholders' equity | $796.3M | $820.8M | $960.0M | $818.0M | $749.4M |
| Cash and investments | $245.4M | $306.8M | $178.8M | $284.5M | $259.5M |
| Total debt | $1.3B | $1.3B | $873.9M | $829.0M | $836.5M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 5, 2026 | Sep 26, 2026 |
| 8-K |
Current report
Results of operations
|
Nov 5, 2026 | Nov 5, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Oct 8, 2026 | Oct 8, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Aug 18, 2026 | Aug 18, 2026 |
| 10-Q | Quarterly report | Aug 6, 2026 | Jun 27, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 6, 2026 | Aug 6, 2026 |
All 1002 Haemonetics Corporation SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.